Simplex Trading, LLC Entera Bio Ltd. Transaction History

Simplex Trading, LLC

$195 Billion
Q3 2025

A detailed history of Simplex Trading, LLC transactions in Entera Bio Ltd. stock. As of the latest transaction made, Simplex Trading, LLC holds 69 shares of ENTX stock, worth $186. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$186

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	BUY	$1.73 - $2.16 $119 - $149	69 New	69 $0
Q2 2024 Jul 25, 2024	SELL	$1.73 - $2.98 $60 - $104	-35 Reduced 11.86%	260 $0
Q1 2024 Apr 25, 2024	BUY	$0.64 - $1.72 $188 - $507	295 New	295 $0
Q3 2023 Nov 01, 2023	SELL	$0.6 - $0.88 $7 - $11	-13 Reduced 13.13%	86 $0
Q2 2023 Aug 04, 2023	BUY	$0.68 - $1.01 $67 - $99	99 New	99 $0
Q2 2022 Aug 03, 2022	SELL	$1.33 - $2.95 $305 - $678	-230 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$1.91 - $3.23 $1,302 - $2,202	-682 Reduced 74.78%	230 $0
Q4 2021 Feb 23, 2022	SELL	$2.82 - $4.79 $52,251 - $88,753	-18,529 Reduced 95.31%	912 $2,000
Q3 2021 Oct 28, 2021	BUY	$4.43 - $6.29 $16,386 - $23,266	3,699 Added 23.5%	19,441 $122,000
Q2 2021 Aug 12, 2021	BUY	$2.92 - $6.5 $45,966 - $102,323	15,742 New	15,742 $94,000

Others Institutions Holding ENTX

# of Institutions

Shares Held

10.8M

Call Options Held

21.1K

Put Options Held

Knoll Capital Management, LLC Miami, FL

5.88M
Shares

$15.9 Million
6.34% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

1.18M
Shares

$3.19 Million
0.0% of portfolio
Marshall Wace, LLP London, X0

627K
Shares

$1.7 Million
0.0% of portfolio
Schonfeld Strategic Advisors LLC New York, NY

567K
Shares

$1.54 Million
0.01% of portfolio
Parkman Healthcare Partners LLC Stamford, CT

281K
Shares

$761,027
0.07% of portfolio

View Full List

About Entera Bio Ltd.

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $78.1M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

More about ENTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account